Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 5/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298754 | 0.86 | DHODH (0.44) | DHODHAURKAAURKBNTRK1SYK | |
| SCHEMBL1298935 | 0.85 | DHODH (0.40) | DHODHAURKAAURKBNTRK1SYK | |
| SCHEMBL1298027 | 0.84 | DHODH (0.42) | DHODHAURKAAURKBNTRK1SYK | |
| SCHEMBL1299027 | 0.83 | DHODH (0.40) | DHODHAURKAAURKBNTRK1SYK | |
| SCHEMBL1299555 | 0.83 | DHODH (0.40) | DHODHAURKAAURKBNTRK1SYK | |
| SCHEMBL1299121 | 0.83 | JAK2 (0.36) | PIK3C3DHODHAURKAAURKBNTRK1 | |
| SCHEMBL1298578 | 0.82 | DHODH (0.39) | DHODHAURKAAURKBNTRK1SYK | |
| SCHEMBL1299082 | 0.81 | DHODH (0.40) | DHODHAURKAAURKBNTRK1SYK | |
| SCHEMBL1298579 | 0.81 | DHODH (0.40) | DHODHAURKAAURKBNTRK1SYK | |
| SCHEMBL1298952 | 0.81 | DHODH (0.40) | DHODHAURKAAURKBNTRK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | PIK3C3 230/4885DHODH 3113/4885AURKA 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.